Advertisement
Canada markets closed
  • S&P/TSX

    21,947.41
    +124.21 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +449.98 (+1.18%)
     
  • CAD/USD

    0.7309
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    77.99
    -0.12 (-0.15%)
     
  • Bitcoin CAD

    87,324.59
    -114.52 (-0.13%)
     
  • CMC Crypto 200

    1,312.63
    +35.65 (+2.79%)
     
  • GOLD FUTURES

    2,310.10
    +1.50 (+0.06%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ

    16,156.33
    +315.33 (+1.99%)
     
  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6788
    -0.0029 (-0.43%)
     

Stocks in play: Intellipharmaceutics International Inc.

Today reported the results of operations for the three months ended February 28, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted. The Company recorded net loss for the three months ended February 28, 2021 of $924,566 or $0.04 per common share, compared with a net loss of $1,747,373 or $0.08 per common share for the three months ended February 29, 2020. The Company recorded revenues of $Nil for the three months ended February 28, 2021 versus $377,554 for the three months ended February 29, 2020. Intellipharmaceutics International Inc. shares T.IPCI are trading unchanged at $0.28.

Read: